Literature DB >> 17531602

The levonorgestrel intrauterine system in nulliparous women.

Sarah Prager1, Philip D Darney.   

Abstract

The levonorgestrel intrauterine system (LNG-IUS) has been used internationally for over 15 years by 7 million women. Concern about providing the LNG-IUS to nulliparous women still exists, despite growing evidence of its safety and efficacy in this population. Expulsion rates do not vary by parity and, although evidence in nulliparas is scant, perforation rates are low in all women. Efficacy of the LNG-IUS is excellent regardless of parity, with less than 1 pregnancy per 100 woman-years of use. Efficacy with immediate post-abortal insertion is also excellent and unvaried by parity. The presence of an LNG-IUS does not increase the risk of PID or infertility in either parous or nulliparous women and the LNG may be protective against infection. Acceptability is high in nulliparous women when compared either to parous LNG-IUS users or to nulliparous users of combined oral contraceptive pills. In conclusion, LNG-IUS is both safe and extremely efficacious for use in nulliparous women.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531602     DOI: 10.1016/j.contraception.2007.01.018

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  10 in total

1.  Duration of use of a levonorgestrel IUS amongst nulliparous and adolescent women.

Authors:  Tiffany Behringer; Matthew F Reeves; Brianna Rossiter; Beatrice A Chen; Eleanor Bimla Schwarz
Journal:  Contraception       Date:  2011-06-30       Impact factor: 3.375

2.  Immediate post-abortion insertion of intrauterine contraceptives (IUC) in a diverse urban population.

Authors:  DeShawn Taylor; Shannon Connolly; Sue Ann Ingles; Carey Watson; Penina Segall-Gutierrez
Journal:  J Immigr Minor Health       Date:  2014-06

Review 3.  Levonorgestrel-Releasing Intrauterine System (52 mg) for Idiopathic Heavy Menstrual Bleeding: A Health Technology Assessment.

Authors: 
Journal:  Ont Health Technol Assess Ser       Date:  2016-11-01

Review 4.  Contraception for cancer survivors.

Authors:  Eleanor Bimla Schwarz; Rachel Hess; James Trussell
Journal:  J Gen Intern Med       Date:  2009-11       Impact factor: 5.128

5.  Feasibility of LNG-IUS in a baboon model.

Authors:  Jason D Bell; Ingrid L Bergin; Melissa F Natavio; Fatima Jibrel; Melissa K Zochowski; William J Weadock; Scott D Swanson; David M Aronoff; Dorothy L Patton
Journal:  Contraception       Date:  2012-10-29       Impact factor: 3.375

6.  The wandering Mirena: laparoscopic retrieval.

Authors:  Mark Erian; Glenda McLaren; David Baartz
Journal:  JSLS       Date:  2011 Jan-Mar       Impact factor: 2.172

7.  Levonorgestrel intrauterine system (Mirena): An emerging tool for conservative treatment of abnormal uterine bleeding.

Authors:  Pallavi C Dhamangaonkar; K Anuradha; Archana Saxena
Journal:  J Midlife Health       Date:  2015 Jan-Mar

8.  The Effect of Age, Parity and Body Mass Index on the Efficacy, Safety, Placement and User Satisfaction Associated With Two Low-Dose Levonorgestrel Intrauterine Contraceptive Systems: Subgroup Analyses of Data From a Phase III Trial.

Authors:  Kristina Gemzell-Danielsson; Dan Apter; Brian Hauck; Thomas Schmelter; Sarah Rybowski; Kimberly Rosen; Anita Nelson
Journal:  PLoS One       Date:  2015-09-17       Impact factor: 3.240

9.  Experience and levels of satisfaction with the levonorgestrel-releasing intrauterine system in China: a prospective multicenter survey.

Authors:  Shuping Zhao; Jihong Deng; Yan Wang; Shiliang Bi; Xiaoye Wang; Wen Qin; Zirong Huang; Li Li; Xin Mi; Liping Han; Qing Chang; Jian Li
Journal:  Patient Prefer Adherence       Date:  2014-10-23       Impact factor: 2.711

10.  Review of the safety, efficacy and patient acceptability of the levonorgestrel-releasing intrauterine system.

Authors:  Chandra Kailasam; David Cahill
Journal:  Patient Prefer Adherence       Date:  2008-02-02       Impact factor: 2.711

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.